03 Oct 2026, 15:02 IST
Aurobindo Pharma Limited
Motilal Oswal (MOFSL) · Buy
The report notes Aurobindo underwent two USFDA inspections in September 2026 resulting in Form 483 observations, and forecasts sales growth of 16.1% YoY.
From HEALTHCARE MOFSL PR PG024, written by Motilal Oswal (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.